Pharvaris also granted an over-allotment option to the underwriters to purchase up to an additional 581,199 of ordinary shares. The over-allotment option has been fully exercised on closing, resulting in total gross proceeds for Pharvaris of approximately USD 132.3 million.
Pharvaris currently intends to use the net proceeds of this offering primarily to fund research and development expenses for its late-stage clinical programmes, the expansion of a sales and marketing team in the U.S. and related commercialisation expenses, as well as for working capital and general corporate purposes. Pharvaris' ordinary shares are listed on NASDAQ (PHVS).
The team further consisted of Nina Kielman, Marije Bader, Daan Hagelstein, Daphne Smiggels, Joppe Schoute and Leanne Meurs.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3).
